The Institute for Clinical and Economic Review (ICER) this week released a report outlining a new annual review which will look to determine whether significant price increases on prescription drugs are supported by clinical evidence.
The “Unsupported Price Increase” report remains in the planning stages, and the organization is seeking public comment to “inform a final version of the analytic protocol.” According to ICER, the first report has been planned for October this year.
“Drug prices are often increased substantially over time in the U.S., and questions are frequently raised regarding whether these price increases are justified,” ICER CMO Dr. David Rind said in a statement. “By identifying drugs with substantial price increases despite no new evidence of added benefit, we hope to make an important first step in providing policymakers with information they can use to advance the public debate on drug price increases.
ICER says it is accepting public comments until 5 p.m. EST Feb. 13.
To read the full press release, click here.
